Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Merck & Co., Inc. — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $79.43, while Merck & Co., Inc. trades at $125.4 (market cap $307.25B). The key difference: Merck & Co., Inc. pays a 2.73% dividend while iShares Core MSCI Emerging Markets ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals.
| IEMG | MRK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $129.52 |
52-Week Low | $59.90 | $77.60 |
Market Cap | — | $307.25B |
Enterprise Value | — | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $77.21, up 0.3% with a bearish technical signal from moving averages and oscillators. The ETF shows strong recent performance with 35% gains over the past year, driven by emerging market inflows and AI-focused technology exposure. Recent news highlights record capital flows into emerging markets and IEMG's 40% technology weighting, though some analysts caution about elevated volatility and concentration risks.
The outlook remains mixed with attractive emerging market valuations and growth opportunities balanced against geopolitical risks and market volatility. Key catalysts include continued AI-driven technology performance and emerging market economic growth, while risks involve US-China tensions and potential market corrections given the ETF's recent strong run.
Merck (MRK) trades at $125.25, down 1.76% on the day, with a neutral technical signal. The company reported strong earnings beats in recent quarters, with Q1 2026 results surpassing expectations. Fundamentals show robust profitability with a 73.91% gross margin and 13.59% net margin, though valuations are elevated with a P/E of 35.04. Recent news highlights the company's strategic acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook is supported by a strong analyst consensus with a $137.30 price target and 68% buy ratings, but risks include high valuation multiples, competitive pressures in oncology, and significant capital expenditure for pipeline development as indicated by negative investing cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
